For decades, pharmaceutical firms have relied on batch manufacturing, a method prone to inefficiencies and long hold times. Continuous manufacturing, an emerging technology supported by the FDA, offers a streamlined, end-to-end production process that enhances efficiency, reduces costs, and improves process control. With the number of continuous production facilities under review quadrupling in the last five years, this session explores the transformative potential of continuous manufacturing in the biotech and pharmaceutical industries. Discover how companies are leveraging this approach to achieve significant reductions in operating costs, waste, and cycle times while enhancing product quality and responding to market demands.
